The definitive merger agreement stipulates that GHO and Ampersand will purchase all outstanding shares of Avid.

The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...

The merger agreement is valued at approximately $1.1 billion. Avid Bioservices, a biologics contract development and manufacturing organization (CDMO), announced on Nov. 6, 2024 that it has entered ...

GHO Capital Partners and Ampersand Capital Partners have agreed to acquire Avid Bioservices, a biologics contract development and manufacturing organization, in an all-cash transaction valued at ...

Avid Bioservices (CDMO) has agreed to be acquired by GHO Capital Partners and Ampersand Capital Partners through a cash deal that values the company at $1.1B. Read more here.

Good morning dealmakers, it’s Obey Martin Manayiti with the US edition of the Wire from the New York newsroom, filling in for ...

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

Detailed price information for Avid Bioservices Inc (CDMO-Q) from The Globe and Mail including charting and trades.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avid Bioservices, Inc. (NASDAQ: CDMO) to ...

Avid Bioservices ( (CDMO) ) just unveiled an announcement. Avid Bioservices, a biologics contract development and manufacturing organization, ...

Avid Bioservices (CDMO), GHO Capital Partners LLP and Ampersand Capital Partners announced they have entered into a definitive merger agreement for Avid to be acquired by funds managed by GHO and ...